Organización Panamericana de la Salud; Organización Mundial de la Salud (Americas)
(2018)
C_WHO
Washington, D.C., EUA, del 23 al 27 de septiembre del 2018
Punto 8.22 del orden del día provisional
CD56/INF/22 31 de agosto del 2018
Original: inglés/español
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.more
Elaborat în cadrul proiectului „Fortificarea controlului tuberculozei în Moldova”, finanţat de către
Fondul Global de combatere a SIDA, Tuberculozei şi Malariei.
Journal of Tuberculosis Research, 2016, 4, 1-8
Published Online March 2016 in SciRes. http://www.scirp.org/journal/jtr
http://dx.doi.org/10.4236/jtr.2016.41001
Technical report
This manual aims to provide information about the methods for investigating outbreaks of hepatitis E, and measures for their prevention and control. In addition, the manual gives information about the causative agent – known as the hepatitis E virus (HEV) – its epidemiology..., clinical manifestations of the disease and diagnosis.more